WP
BOLT icon

Woodline Partners’s Bolt Biotherapeutics BOLT Stock Holding History

Woodline Partners’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,168
Closed -$1.98M – 733
2021
Q4 		$1.98M Buy
20,168
+451
+2% +$85.6K 0.03% 418
2021
Q3 		$4.99M Buy
19,717
+633
+3% +$179K 0.08% 250
2021
Q2 		$5.9M Buy
19,084
+378
+2% +$153K 0.11% 202
2021
Q1 		$12.3M Buy
+18,706
New +$12.2M 0.27% 99

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ESCM
Echo Street Capital Management New York $747M AUM 24.25% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Woodline Partners's BOLT Position: Q1 2022 in Review

Woodline Partners sold out of Bolt Biotherapeutics (BOLT) in Q1 2022, closing a stake of 20,168 shares — an estimated $1.98M sold.

Woodline Partners first reported a position in BOLT in Q1 2021 and held it in 4 quarters. The position peaked at $12.3M in Q1 2021. 65 funds tracked by Wall St. Rank hold BOLT as of Q1 2022.

  • Woodline Partners reported no remaining Bolt Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Woodline Partners sold 20,168 Bolt Biotherapeutics shares in Q1 2022, an estimated $1.98M.
  • Woodline Partners first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 4 quarters.
  • Woodline Partners's Bolt Biotherapeutics position peaked at $12.3M in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2022.

Based on Woodline Partners's 13F filing for Q1 2022, filed 16 May 2022.